Skip to Content
Merck

Emerging therapies in rosacea.

Journal of the American Academy of Dermatology (2013-11-28)
Alison Layton, Diane Thiboutot
ABSTRACT

Rosacea is a common skin disorder with multiple symptoms. The emergence of research that furthers understanding of pathophysiological mechanisms has created new targets for disease treatment. Specifically, there is a need for new treatments that address the various erythematic symptoms associated with rosacea. Systemic and topical therapies have both yielded positive results in treating rosacea with various medications. Subantimicrobial-dose doxycycline is one such promising treatment. Development of novel products in the near future should help achieve more satisfactory outcomes for patients.

MATERIALS
Product Number
Brand
Product Description

Supelco
Doxycycline hyclate, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Doxycycline hyclate
Supelco
Doxycycline hyclate, VETRANAL®, analytical standard
Sigma-Aldrich
Ivermectin
Sigma-Aldrich
Doxycycline monohydrate
Supelco
Permethrin, PESTANAL®, analytical standard
Ivermectin, European Pharmacopoeia (EP) Reference Standard